Scientists and federal health officials are working to understand why some people are experiencing recurring symptoms after taking the antiviral drug. In a recent clinical trial, about 2 percent of high-risk patients who received Paxlovid saw viral levels rebound, Pfizer leaders said. This figure was comparable to that of the control group, suggesting the phenomenon is not caused by the medication.
“Paxlovid does what it has to do: It reduces the viral load. Then your body is supposed to do the job,” Pfizer CEO Albert Bourla told Bloomberg. In the rare case that virus levels rebound, “then you give a second course, like you do with antibiotics, and that’s it,” he said.
Paxlovid is available under an emergency use authorization by the FDA, and the drug’s prescribing directions say it’s “not authorized for use for longer than [five] consecutive days.” The FDA did not immediately respond to Bloomberg‘s request for comment on how the drug should be prescribed for patients with rebounding symptoms.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
